Occam Places Padma Sundar as CBO at ChromaCode
ChromaCode, a private molecular diagnostics company with a bioinformatics focus, has added Padma Sundar as Chief Business Officer to lead commercialization. The company was founded by Illumina veteran Alex Dickinson and has NEA and Northpond as lead investors.
Padma brings deep knowledge of the cancer space and nearly two decades of rich accomplishment transforming diagnostic organizations with disruptive technologies into revenue stage companies with market leading tests. She most recently served as Chief Commercial Officer of Oncocyte, a precision diagnostics company.
Her career began in the healthcare practice of McKinsey &Co.
Padma earned both an MBA and an MPH from the University of California-Berkeley after completing her undergraduate degree in Chemistry at Delhi University.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.